Aberrant miRNAs Regulate the Biological Hallmarks of Glioblastoma

Achyut, B. R., Angara, K., Jain, M., Borin, T. F., Rashid, M. H., Iskander, A. S. M., et al. (2017). Canonical NFkappaB signaling in myeloid cells is required for the glioblastoma growth. Scientific Reports, 7(1), 13754. https://doi.org/10.1038/s41598-017-14079-4.CrossRefPubMedPubMedCentral

Alt, J. R., Cleveland, J. L., Hannink, M., & Diehl, J. A. (2000). Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes & Development, 14(24), 3102–3114.CrossRef

Aoki, K., Nakamura, H., Suzuki, H., Matsuo, K., Kataoka, K., Shimamura, T., et al. (2018). Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro-Oncology, 20(1), 66–77. https://doi.org/10.1093/neuonc/nox132.CrossRefPubMed

Arena, G., Cisse, M. Y., Pyrdziak, S., Chatre, L., Riscal, R., Fuentes, M., et al. (2018). Mitochondrial MDM2 regulates respiratory complex I activity independently of p53. Molecular Cell, 69(4), 594–609. https://doi.org/10.1016/j.molcel.2018.01.023.CrossRefPubMed

Asuthkar, S., Velpula, K. K., Chetty, C., Gorantla, B., & Rao, J. S. (2012). Epigenetic regulation of miRNA-211 by MMP-9 governs glioma cell apoptosis, chemosensitivity and radiosensitivity. Oncotarget, 3(11), 1439–1454. https://doi.org/10.18632/oncotarget.683.CrossRefPubMedPubMedCentral

Bai, M., Yu, N. Z., Long, F., Feng, C., & Wang, X. J. (2016). Effects of CDKN2A (p16INK4A/p14ARF) over-expression on proliferation and migration of human melanoma A375 cells. Cellular Physiology and Biochemistry, 40(6), 1367–1376. https://doi.org/10.1159/000453189.CrossRefPubMed

Bamford, S., Dawson, E., Forbes, S., Clements, J., Pettett, R., Dogan, A., et al. (2004). The COSMIC (catalogue of somatic mutations in cancer) database and website. British Journal of Cancer, 91(2), 355–358. https://doi.org/10.1038/sj.bjc.6601894.CrossRefPubMedPubMedCentral

Ben-Neriah, Y., & Karin, M. (2011). Inflammation meets cancer, with NF-kappaB as the matchmaker. Nature Immunology, 12(8), 715–723. https://doi.org/10.1038/ni.2060.CrossRefPubMed

Berrout, J., Kyriakopoulou, E., Moparthi, L., Hogea, A. S., Berrout, L., Ivan, C., et al. (2017). TRPA1-FGFR2 binding event is a regulatory oncogenic driver modulated by miRNA-142-3p. Nature Communication, 8(1), 947. https://doi.org/10.1038/s41467-017-00983-w.CrossRef

Berzins, S. P., & Ritchie, D. S. (2014). Natural killer T cells: Drivers or passengers in preventing human disease? Nature Reviews Immunology, 14(9), 640–646. https://doi.org/10.1038/nri3725.CrossRefPubMed

Bhowmick, N. A., Ghiassi, M., Bakin, A., Aakre, M., Lundquist, C. A., Engel, M. E., et al. (2001). Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. Molecular Biology of the Cell (MBoC), 12(1), 27–36.CrossRef

Bian, C. X., Shi, Z., Meng, Q., Jiang, Y., Liu, L. Z., & Jiang, B. H. (2010). P70S6K 1 regulation of angiogenesis through VEGF and HIF-1alpha expression. Biochemical and Biophysical Research Communications, 398(3), 395–399. https://doi.org/10.1016/j.bbrc.2010.06.080.CrossRefPubMedPubMedCentral

Bier, A., Giladi, N., Kronfeld, N., Lee, H. K., Cazacu, S., Finniss, S., et al. (2013). MicroRNA-137 is downregulated in glioblastoma and inhibits the stemness of glioma stem cells by targeting RTVP-1. Oncotarget, 4(5), 665–676. https://doi.org/10.18632/oncotarget.928.CrossRefPubMedPubMedCentral

Cai, J., Zhao, J., Zhang, N., Xu, X., Li, R., Yi, Y., et al. (2015). MicroRNA-542-3p suppresses tumor cell invasion via targeting AKT pathway in human astrocytoma. The Journal of Biological Chemistry, 290(41), 24678–24688. https://doi.org/10.1074/jbc.M115.649004.CrossRefPubMedPubMedCentral

Cai, J. J., Qi, Z. X., Chen, L. C., Yao, Y., Gong, Y., & Mao, Y. (2016). miR-124 suppresses the migration and invasion of glioma cells in vitro via Capn4. Oncology Reports, 35(1), 284–290. https://doi.org/10.3892/or.2015.4355.CrossRefPubMed

Callahan, M. K., & Wolchok, J. D. (2013). At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. Journal of Leukocyte Biology, 94(1), 41–53. https://doi.org/10.1189/jlb.1212631.CrossRefPubMedPubMedCentral

Cancer Genome Atlas Research Network. (2008). Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 455(7216), 1061–1068. https://doi.org/10.1038/nature07385.CrossRef

Chakrabarti, M., Klionsky, D. J., & Ray, S. K. (2016). miR-30e blocks autophagy and acts synergistically with proanthocyanidin for inhibition of AVEN and BIRC6 to increase apoptosis in glioblastoma stem cells and glioblastoma SNB19 cells. PLoS ONE, 11(7), e0158537. https://doi.org/10.1371/journal.pone.0158537.CrossRefPubMedPubMedCentral

Chen, J., Fu, X., Wan, Y., Wang, Z., Jiang, D., & Shi, L. (2014a). miR-125b inhibitor enhance the chemosensitivity of glioblastoma stem cells to temozolomide by targeting Bak1. Tumour Biology, 35(7), 6293–6302. https://doi.org/10.1007/s13277-014-1821-4.CrossRefPubMed

Chen, L., Han, L., Zhang, K., Shi, Z., Zhang, J., Zhang, A., et al. (2012a). VHL regulates the effects of miR-23b on glioma survival and invasion via suppression of HIF-1alpha/VEGF and beta-catenin/Tcf-4 signaling. Neuro-Oncology, 14(8), 1026–1036. https://doi.org/10.1093/neuonc/nos122.CrossRefPubMedPubMedCentral

Chen, L., Zhang, J., Feng, Y., Li, R., Sun, X., Du, W., et al. (2012b). MiR-410 regulates MET to influence the proliferation and invasion of glioma. The International Journal of Biochemistry & Cell Biology, 44(11), 1711–1717. https://doi.org/10.1016/j.biocel.2012.06.027.CrossRef

Chen, L., Zhang, K., Shi, Z., Zhang, A., Jia, Z., Wang, G., et al. (2014b). A lentivirus-mediated miR-23b sponge diminishes the malignant phenotype of glioma cells in vitro and in vivo. Oncology Reports, 31(4), 1573–1580. https://doi.org/10.3892/or.2014.3012.CrossRefPubMed

Chen, L., Zhang, R., Li, P., Liu, Y., Qin, K., Fa, Z. Q., et al. (2013). P53-induced microRNA-107 inhibits proliferation of glioma cells and down-regulates the expression of CDK6 and Notch-2. Neuroscience Letters, 534, 327–332. https://doi.org/10.1016/j.neulet.2012.11.047.CrossRefPubMed

Chen, W., Yu, Q., Chen, B., Lu, X., & Li, Q. (2016). The prognostic value of a seven-microRNA classifier as a novel biomarker for the prediction and detection of recurrence in glioma patients. Oncotarget, 7(33), 53392–53413. https://doi.org/10.18632/oncotarget.10534.CrossRefPubMedPubMedCentral

Chen, Y., Li, R., Pan, M., Shi, Z., Yan, W., Liu, N., et al. (2017). MiR-181b modulates chemosensitivity of glioblastoma multiforme cells to temozolomide by targeting the epidermal growth factor receptor. Journal of Neuro-Oncology, 133(3), 477–485. https://doi.org/10.1007/s11060-017-2463-3.CrossRefPubMed

Chen, Z. J. (2012). Ubiquitination in signaling to and activation of IKK. Immunological Reviews, 246(1), 95–106. https://doi.org/10.1111/j.1600-065X.2012.01108.x.CrossRefPubMedPubMedCentral

Cheng, L., Huang, Z., Zhou, W., Wu, Q., Donnola, S., Liu, J. K., et al. (2013). Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell, 153(1), 139–152. https://doi.org/10.1016/j.cell.2013.02.021.CrossRefPubMedPubMedCentral

Cheng, Z. X., Yin, W. B., & Wang, Z. Y. (2017). MicroRNA-132 induces temozolomide resistance and promotes the formation of cancer stem cell phenotypes by targeting tumor suppressor candidate 3 in glioblastoma. International Journal of Molecular Medicine, 40(5), 1307–1314. https://doi.org/10.3892/ijmm.2017.3124.CrossRefPubMedPubMedCentral

Chung, H. J., Choi, Y. E., Kim, E. S., Han, Y. H., Park, M. J., & Bae, I. H. (2015). miR-29b attenuates tumorigenicity and stemness maintenance in human glioblastoma multiforme by directly targeting BCL2L2. Oncotarget, 6(21), 18429–18444. https://doi.org/10.18632/oncotarget.4384.CrossRefPubMedPubMedCentral

Ciafre, S. A., Galardi, S., Mangiola, A., Ferracin, M., Liu, C. G., Sabatino, G., et al. (2005). Extensive modulation of a set of microRNAs in primary glioblastoma. Biochemical and Biophysical Research Communications, 334(4), 1351–1358. https://doi.org/10.1016/j.bbrc.2005.07.030.CrossRefPubMed

Codo, P., Weller, M., Meister, G., Szabo, E., Steinle, A., Wolter, M., et al. (2014). MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape. Oncotarget, 5(17), 7651–7662. https://doi.org/10.18632/oncotarget.2287.CrossRefPubMedPubMedCentral

Coleman, K. G., Wautlet, B. S., Morrissey, D., Mulheron, J., Sedman, S. A., Brinkley, P., et al. (1997). Identification of CDK4 sequences involved in cyclin D1 and p16 binding. The Journal of Biological Chemistry, 272(30), 18869–18874.CrossRef

Colwell, N., Larion, M., Giles, A. J., Seldomridge, A. N., Sizdahkhani, S., Gilbert, M. R., et al. (2017). Hypoxia in the glioblastoma microenvironment: Shaping the phenotype of cancer stem-like cells. Neuro-Oncology, 19(7), 887–896. https://doi.org/10.1093/neuonc/now258.CrossRefPubMedPubMedCentral

Comincini, S., Allavena, G., Palumbo, S., Morini, M., Durando, F., Angeletti, F., et al. (2013). microRNA-17 regulates the expression of ATG7 and modulates the autophagy process, improving the sensitivity to temozolomide and low-dose ionizing radiation treatments in human glioblastoma cells. Cancer Biology & Therapy, 14(7), 574–586. https://doi.org/10.4161/cbt.24597.CrossRef

Crane, C. A., Han, S. J., Barry, J. J., Ahn, B. J., Lanier, L. L., & Parsa, A. T. (2010). TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro-Oncology, 12(1), 7–13. https://doi.org/10.1093/neuonc/nop009.CrossRefPubMed

Dai, D. W., Lu, Q., Wang, L. X., Zhao, W. Y., Cao, Y. Q., Li, Y. N., et al. (2013). Decreased miR-106a inhibits glioma cell glucose uptake and proliferation by targeting SLC2A3 in GBM. BMC Cancer, 13, 478. https://doi.org/10.1186/1471-2407-13-478.CrossRefPubMedPubMedCentral

de Planell-Saguer, M., & Rodicio, M. C. (2013). Detection methods for microRNAs in clinic practice. Clinical Biochemistry, 46, 10–11. https://doi.org/10.1016/j.clinbiochem.2013.02.017.CrossRef

Deng, G., Zhou, F., Wu, Z., Zhang, F., Niu, K., Kang, Y., et al. (2018). Inhibition of cancer cell migration with CuS@ mSiO2-PEG nanoparticles by repressing MMP-2/MMP-9 expression. International Journal of Nanomedicine, 13, 103–116. https://doi.org/10.2147/IJN.S148487.CrossRefPubMed

Deng, X., Ma, L., Wu, M., Zhang, G., Jin, C., Guo, Y., et al. (2013). miR-124 radiosensitizes human glioma cells by targeting CDK4. Journal of Neuro-Oncology, 114(3), 263–274. https://doi.org/10.1007/s11060-013-1179-2.CrossRefPubMed

Dontula, R., Dinasarapu, A., Chetty, C., Pannuru, P., Herbert, E., Ozer, H., et al. (2013). MicroRNA 203 modulates glioma cell migration via Robo1/ERK/MMP-9 signaling. Genes and Cancer, 4(7–8), 285–296. https://doi.org/10.1177/1947601913500141.CrossRefPubMed

Duan, J., Zhou, K., Tang, X., Duan, J., & Zhao, L. (2016). MicroRNA-34a inhibits cell proliferation and induces cell apoptosis of glioma cells via targeting of Bcl-2. Molecular Medicine Reports, 14(1), 432–438. https://doi.org/10.3892/mmr.2016.5255.CrossRefPubMed

Eckel-Passow, J. E., Lachance, D. H., Molinaro, A. M., Walsh, K. M., Decker, P. A., Sicotte, H., et al. (2015). Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. The New England Journal of Medicine, 372(26), 2499–2508. https://doi.org/10.1056/NEJMoa1407279.CrossRefPubMedPubMedCentral

Egeblad, M., & Werb, Z. (2002). New functions for the matrix metalloproteinases in cancer progression. Nature Review Cancer, 2(3), 161–174. https://doi.org/10.1038/nrc745.CrossRef

Eisele, G., Wischhusen, J., Mittelbronn, M., Meyermann, R., Waldhauer, I., Steinle, A., et al. (2006). TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. Brain, 129(Pt 9), 2416–2425. https://doi.org/10.1093/brain/awl205.CrossRefPubMed

Ewan, L. C., Jopling, H. M., Jia, H., Mittar, S., Bagherzadeh, A., Howell, G. J., et al. (2006). Intrinsic tyrosine kinase activity is required for vascular endothelial growth factor receptor 2 ubiquitination, sorting and degradation in endothelial cells. Traffic, 7(9), 1270–1282.CrossRef

Fan, X., Khaki, L., Zhu, T. S., Soules, M. E., Talsma, C. E., Gul, N., et al. (2010). NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells, 28(1), 5–16. https://doi.org/10.1002/stem.254.CrossRefPubMedPubMedCentral

Figueroa, J., Phillips, L. M., Shahar, T., Hossain, A., Gumin, J., Kim, H., et al. (2017). Exosomes from glioma-associated mesenchymal stem cells increase the tumorigenicity of glioma stem-like cells via transfer of miR-1587. Cancer Research, 77(21), 5808–5819. https://doi.org/10.1158/0008-5472.CAN-16-2524.CrossRefPubMedPubMedCentral

Floyd, D. H., Zhang, Y., Dey, B. K., Kefas, B., Breit, H., Marks, K., et al. (2014). Novel anti-apoptotic microRNAs 582-5p and 363 promote human glioblastoma stem cell survival via direct inhibition of caspase 3, caspase 9, and Bim. PLoS ONE, 9(5), e96239. https://doi.org/10.1371/journal.pone.0096239.CrossRefPubMedPubMedCentral

Freeman, A. K., & Morrison, D. K. (2011). 14-3-3 proteins: Diverse functions in cell proliferation and cancer progression. Seminars in Cell and Developmental Biology, 22(7), 681–687. https://doi.org/10.1016/j.semcdb.2011.08.009.CrossRefPubMed

Gabriely, G., Wurdinger, T., Kesari, S., Esau, C. C., Burchard, J., Linsley, P. S., et al. (2008). MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Molecular Cell Biology, 28(17), 5369–5380. https://doi.org/10.1128/MCB.00479-08.CrossRef

Gao, X., Zhu, X., Sun, Y., & Liu, J. (2017). MicroRNA141 inhibits the selfrenewal of glioblastoma stem cells via Jagged1. Molecular Medicine Reports, 16(1), 167–173. https://doi.org/10.3892/mmr.2017.6598.CrossRefPubMedPubMedCentral

Gao, Y. T., Chen, X. B., & Liu, H. L. (2016). Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing MGMT expression. Scientific Reports, 6, 32972. https://doi.org/10.1038/srep32972.CrossRefPubMedPubMedCentral

Genovese, G., Ergun, A., Shukla, S. A., Campos, B., Hanna, J., Ghosh, P., et al. (2012). microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-beta signaling in glioblastoma. Cancer Discovery, 2(8), 736–749. https://doi.org/10.1158/2159-8290.CD-12-0111.CrossRefPubMedPubMedCentral

Gheldof, A., Hulpiau, P., van Roy, F., De Craene, B., & Berx, G. (2012). Evolutionary functional analysis and molecular regulation of the ZEB transcription factors. Cellular and Molecular Life Sciences, 69(15), 2527–2541. https://doi.org/10.1007/s00018-012-0935-3.CrossRefPubMed

Gong, W., Zheng, J., Liu, X., Ma, J., Liu, Y., & Xue, Y. (2016). Knockdown of NEAT1 restrained the malignant progression of glioma stem cells by activating microRNA let-7e. Oncotarget, 7(38), 62208–62223. https://doi.org/10.18632/oncotarget.11403.CrossRefPubMedPubMedCentral

Gressner, O., Schilling, T., Lorenz, K., Schulze Schleithoff, E., Koch, A., Schulze-Bergkamen, H., et al. (2005). TAp63alpha induces apoptosis by activating signaling via death receptors and mitochondria. EMBO Journal, 24(13), 2458–2471. https://doi.org/10.1038/sj.emboj.7600708.CrossRefPubMed

Guo, P., Lan, J., Ge, J., Nie, Q., Guo, L., Qiu, Y., et al. (2014). MiR-26a enhances the radiosensitivity of glioblastoma multiforme cells through targeting of ataxia-telangiectasia mutated. Experimental Cell Research, 320(2), 200–208. https://doi.org/10.1016/j.yexcr.2013.10.020.CrossRefPubMed

Guo, X., Xu, S., Gao, X., Wang, J., Xue, H., Chen, Z., et al. (2017). Macrophage migration inhibitory factor promotes vasculogenic mimicry formation induced by hypoxia via CXCR4/AKT/EMT pathway in human glioblastoma cells. Oncotarget, 8(46), 80358–80372. https://doi.org/10.18632/oncotarget.18673.CrossRefPubMedPubMedCentral

Guo, X., Xue, H., Guo, X., Gao, X., Xu, S., Yan, S., et al. (2015). MiR224-3p inhibits hypoxia-induced autophagy by targeting autophagy-related genes in human glioblastoma cells. Oncotarget, 6(39), 41620–41637. https://doi.org/10.18632/oncotarget.5871.CrossRefPubMedPubMedCentral

Guo, Y., Yan, K., Fang, J., Qu, Q., Zhou, M., & Chen, F. (2013). Let-7b expression determines response to chemotherapy through the regulation of cyclin D1 in glioblastoma. Journal of Experimental & Clinical Cancer Research, 32, 41. https://doi.org/10.1186/1756-9966-32-41.CrossRef

Gutnikova, A. R., Babakhanova, V. B., Kamalova, G. A., Leshchenko, N. A., & Kasymov, A. (1984). Changes in the functional status of the myocardium after left ventricular bypass. Kardiologiia, 24(1), 93–94.PubMed

Gyorffy, B., & Schafer, R. (2010). Biomarkers downstream of RAS: A search for robust transcriptional targets. Current Cancer Drug Targets, 10(8), 858–868.CrossRef

Haddadi, N., Lin, Y., Travis, G., Simpson, A. M., McGowan, E. M., & Nassif, N. T. (2018). PTEN/PTENP1: ‘Regulating the regulator of RTK-dependent PI3K/Akt signalling’, new targets for cancer therapy. Molecular Cancer, 17(1), 37. https://doi.org/10.1186/s12943-018-0803-3.CrossRefPubMedPubMedCentral

Hallett, M. A., Venmar, K. T., & Fingleton, B. (2012). Cytokine stimulation of epithelial cancer cells: The similar and divergent functions of IL-4 and IL-13. Cancer Research, 72(24), 6338–6343. https://doi.org/10.1158/0008-5472.CAN-12-3544.CrossRefPubMedPubMedCentral

Hamilton, J. D., Rapp, M., Schneiderhan, T., Sabel, M., Hayman, A., Scherer, A., et al. (2014). Glioblastoma multiforme metastasis outside the CNS: Three case reports and possible mechanisms of escape. Journal of Clinical Oncology, 32(22), e80–e84. https://doi.org/10.1200/JCO.2013.48.7546.CrossRefPubMed

Hanahan, D., & Folkman, J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell, 86(3), 353–364.CrossRef

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674. https://doi.org/10.1016/j.cell.2011.02.013.CrossRef

Hao, J., Zhang, C., Zhang, A., Wang, K., Jia, Z., Wang, G., et al. (2012). miR-221/222 is the regulator of Cx43 expression in human glioblastoma cells. Oncology Reports, 27(5), 1504–1510. https://doi.org/10.3892/or.2012.1652.CrossRefPubMed

Harris, A. L. (2002). Hypoxia: A key regulatory factor in tumour growth. Nature Review Cancer, 2(1), 38–47. https://doi.org/10.1038/nrc704.CrossRef

Hayakawa, Y., Kelly, J. M., Westwood, J. A., Darcy, P. K., Diefenbach, A., Raulet, D., et al. (2002). Cutting edge: Tumor rejection mediated by NKG2D receptor-ligand interaction is dependent upon perforin. The Journal of Immunology, 169(10), 5377–5381.CrossRef

Hayes, J., Thygesen, H., Tumilson, C., Droop, A., Boissinot, M., Hughes, T. A., et al. (2015). Prediction of clinical outcome in glioblastoma using a biologically relevant nine-microRNA signature. Molecular Oncology, 9(3), 704–714. https://doi.org/10.1016/j.molonc.2014.11.004.CrossRefPubMed

He, S., Yang, S., Niu, M., Zhong, Y., Dan, G., Zhang, Y., et al. (2018). HMG-box transcription factor 1: A positive regulator of the G1/S transition through the Cyclin-CDK-CDKI molecular network in nasopharyngeal carcinoma. Cell Death & Disease, 9(2), 100. https://doi.org/10.1038/s41419-017-0175-4.CrossRef

He, X., Liu, Z., Peng, Y., & Yu, C. (2016). MicroRNA-181c inhibits glioblastoma cell invasion, migration and mesenchymal transition by targeting TGF-beta pathway. Biochemical and Biophysical Research Communications, 469(4), 1041–1048. https://doi.org/10.1016/j.bbrc.2015.12.021.CrossRefPubMed

Hegde, S., Fox, L., Wang, X., & Gumperz, J. E. (2010). Autoreactive natural killer T cells: Promoting immune protection and immune tolerance through varied interactions with myeloid antigen-presenting cells. Immunology, 130(4), 471–483. https://doi.org/10.1111/j.1365-2567.2010.03293.x.CrossRefPubMedPubMedCentral

Hegi, M. E., Diserens, A. C., Gorlia, T., Hamou, M. F., de Tribolet, N., Weller, M., et al. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. The New England Journal of Medicine, 352(10), 997–1003. https://doi.org/10.1056/NEJMoa043331.CrossRefPubMed

Hou, Z., Peng, H., White, D. E., Wang, P., Lieberman, P. M., Halazonetis, T., et al. (2010). 14-3-3 binding sites in the snail protein are essential for snail-mediated transcriptional repression and epithelial-mesenchymal differentiation. Cancer Research, 70(11), 4385–4393. https://doi.org/10.1158/0008-5472.CAN-10-0070.CrossRefPubMedPubMedCentral

Hsieh, P. N., Sweet, D. R., Fan, L., & Jain, M. K. (2017). Aging and the Kruppel-like factors. Trends in Cell & Molecular Biology, 12, 1–15.

Hu, B., Wang, Q., Wang, Y. A., Hua, S., Sauve, C. G., Ong, D., et al. (2016a). Epigenetic activation of WNT5A drives glioblastoma stem cell differentiation and invasive growth. Cell, 167(5), 1281–1295. https://doi.org/10.1016/j.cell.2016.10.039.CrossRefPubMedPubMedCentral

Hu, J., Sun, T., Wang, H., Chen, Z., Wang, S., Yuan, L., et al. (2016b). MiR-215 is induced post-transcriptionally via HIF-drosha complex and mediates glioma-initiating cell adaptation to hypoxia by targeting KDM1B. Cancer Cell, 29(1), 49–60. https://doi.org/10.1016/j.ccell.2015.12.005.CrossRefPubMedPubMedCentral

Hu, L. S., Ning, S., Eschbacher, J. M., Baxter, L. C., Gaw, N., Ranjbar, S., et al. (2017a). Radiogenomics to characterize regional genetic heterogeneity in glioblastoma. Neuro-Oncology, 19(1), 128–137. https://doi.org/10.1093/neuonc/now135.CrossRefPubMed

Hu, S., Chen, H., Zhang, Y., Wang, C., Liu, K., Wang, H., et al. (2017b). MicroRNA-520c inhibits glioma cell migration and invasion by the suppression of transforming growth factor-beta receptor type 2. Oncology Reports, 37(3), 1691–1697. https://doi.org/10.3892/or.2017.5421.CrossRefPubMed

Huang, S. X., Zhao, Z. Y., Weng, G. H., He, X. Y., Wu, C. J., Fu, C. Y., et al. (2017). Upregulation of miR-181a suppresses the formation of glioblastoma stem cells by targeting the Notch2 oncogene and correlates with good prognosis in patients with glioblastoma multiforme. Biochemical and Biophysical Research Communications, 486(4), 1129–1136. https://doi.org/10.1016/j.bbrc.2017.04.008.CrossRefPubMed

Hui, W., Yuntao, L., Lun, L., WenSheng, L., ChaoFeng, L., HaiYong, H., et al. (2013). MicroRNA-195 inhibits the proliferation of human glioma cells by directly targeting cyclin D1 and cyclin E1. PLoS ONE, 8(1), e54932. https://doi.org/10.1371/journal.pone.0054932.CrossRefPubMedPubMedCentral

Huse, J. T., Brennan, C., Hambardzumyan, D., Wee, B., Pena, J., Rouhanifard, S. H., et al. (2009). The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and facilitates gliomagenesis in vivo. Genes & Development, 23(11), 1327–1337. https://doi.org/10.1101/gad.1777409.CrossRef

Intlekofer, A. M., & Thompson, C. B. (2013). At the bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. Journal of Leukocyte Biology, 94(1), 25–39. https://doi.org/10.1189/jlb.1212621.CrossRefPubMedPubMedCentral

Ishii, N., Maier, D., Merlo, A., Tada, M., Sawamura, Y., Diserens, A. C., et al. (1999). Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathology, 9(3), 469–479.CrossRef

Jaraiz-Rodriguez, M., Tabernero, M. D., Gonzalez-Tablas, M., Otero, A., Orfao, A., Medina, J. M., et al. (2017). A short region of Connexin43 reduces human glioma stem cell migration, invasion, and survival through Src, PTEN, and FAK. Stem Cell Reports, 9(2), 451–463. https://doi.org/10.1016/j.stemcr.2017.06.007.CrossRefPubMedPubMedCentral

Jia, Z., Wang, K., Zhang, A., Wang, G., Kang, C., Han, L., et al. (2013). miR-19a and miR-19b overexpression in gliomas. Pathology and Oncology Research, 19(4), 847–853. https://doi.org/10.1007/s12253-013-9653-x.CrossRefPubMed

Jiang, C., Shen, F., Du, J., Hu, Z., Li, X., Su, J., et al. (2016). MicroRNA-564 is downregulated in glioblastoma and inhibited proliferation and invasion of glioblastoma cells by targeting TGF-beta1. Oncotarget, 7(35), 56200–56208. https://doi.org/10.18632/oncotarget.8987.CrossRefPubMedPubMedCentral

Johansen, M. D., Rochat, P., Law, I., Scheie, D., Poulsen, H. S., & Muhic, A. (2016). Presentation of two cases with early extracranial metastases from glioblastoma and review of the literature. Case Reports in Oncological Medicine, 2016, 8190950. https://doi.org/10.1155/2016/8190950.CrossRefPubMedPubMedCentral

Kanamori, M., Kawaguchi, T., Nigro, J. M., Feuerstein, B. G., Berger, M. S., Miele, L., et al. (2007). Contribution of Notch signaling activation to human glioblastoma multiforme. Journal of Neurosurgery, 106(3), 417–427. https://doi.org/10.3171/jns.2007.106.3.417.CrossRefPubMed

Kang, H., Lee, M., & Jang, S. W. (2013). Celastrol inhibits TGF-beta1-induced epithelial-mesenchymal transition by inhibiting Snail and regulating E-cadherin expression. Biochemical and Biophysical Research Communications, 437(4), 550–556. https://doi.org/10.1016/j.bbrc.2013.06.113.CrossRefPubMed

Kefas, B., Comeau, L., Erdle, N., Montgomery, E., Amos, S., & Purow, B. (2010). Pyruvate kinase M2 is a target of the tumor-suppressive microRNA-326 and regulates the survival of glioma cells. Neuro-Oncology, 12(11), 1102–1112. https://doi.org/10.1093/neuonc/noq080.CrossRefPubMedPubMedCentral

Kefas, B., Godlewski, J., Comeau, L., Li, Y., Abounader, R., Hawkinson, M., et al. (2008). microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Research, 68(10), 3566–3572. https://doi.org/10.1158/0008-5472.CAN-07-6639.CrossRefPubMed

Kim, H., Huang, W., Jiang, X., Pennicooke, B., Park, P. J., & Johnson, M. D. (2010). Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship. Proceedings of the National Academy of Sciences of the United States of America, 107(5), 2183–2188. https://doi.org/10.1073/pnas.0909896107.CrossRefPubMedPubMedCentral

Kim, J., Zhang, Y., Skalski, M., Hayes, J., Kefas, B., Schiff, D., et al. (2014). microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma. Cancer Research, 74(5), 1541–1553. https://doi.org/10.1158/0008-5472.CAN-13-1449.CrossRefPubMedPubMedCentral

Kitamura, H., Ohno, Y., Toyoshima, Y., Ohtake, J., Homma, S., Kawamura, H., et al. (2017). Interleukin-6/STAT3 signaling as a promising target to improve the efficacy of cancer immunotherapy. Cancer Science, 108(10), 1947–1952. https://doi.org/10.1111/cas.13332.CrossRefPubMedPubMedCentral

Knudsen, E. S., & Knudsen, K. E. (2008). Tailoring to RB: Tumour suppressor status and therapeutic response. Nature Review Cancer, 8(9), 714–724. https://doi.org/10.1038/nrc2401.CrossRef

Knutson, K. L., & Disis, M. L. (2005). Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunology, Immunotherapy, 54(8), 721–728. https://doi.org/10.1007/s00262-004-0653-2.CrossRefPubMed

Kosaka, A., Ohkuri, T., Ikeura, M., Kohanbash, G., & Okada, H. (2015). Transgene-derived overexpression of miR-17-92 in CD8+ T cells confers enhanced cytotoxic activity. Biochemical and Biophysical Research Communications, 458(3), 549–554. https://doi.org/10.1016/j.bbrc.2015.02.003.CrossRefPubMedPubMedCentral

Kota, J., Chivukula, R. R., O’Donnell, K. A., Wentzel, E. A., Montgomery, C. L., Hwang, H. W., et al. (2009). Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell, 137(6), 1005–1017. https://doi.org/10.1016/j.cell.2009.04.021.CrossRefPubMedPubMedCentral

Kotzsch, M., Farthmann, J., Meye, A., Fuessel, S., Baretton, G., Tjan-Heijnen, V. C., et al. (2005). Prognostic relevance of uPAR-del4/5 and TIMP-3 mRNA expression levels in breast cancer. European Journal of Cancer, 41(17), 2760–2768. https://doi.org/10.1016/j.ejca.2005.09.002.CrossRefPubMed

Kouhkan, F., Mobarra, N., Soufi-Zomorrod, M., Keramati, F., Hosseini Rad, S. M., Fathi-Roudsari, M., et al. (2016). MicroRNA-129-1 acts as tumour suppressor and induces cell cycle arrest of GBM cancer cells through targeting IGF2BP3 and MAPK1. Journal of Medical Genetics, 53(1), 24–33. https://doi.org/10.1136/jmedgenet-2015-103225.CrossRefPubMed

Kouri, F. M., Hurley, L. A., Daniel, W. L., Day, E. S., Hua, Y., Hao, L., et al. (2015). miR-182 integrates apoptosis, growth, and differentiation programs in glioblastoma. Genes & Development, 29(7), 732–745. https://doi.org/10.1101/gad.257394.114.CrossRef

Kushwaha, D., Ramakrishnan, V., Ng, K., Steed, T., Nguyen, T., Futalan, D., et al. (2014). A genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA in glioblastomas. Oncotarget, 5(12), 4026–4039. https://doi.org/10.18632/oncotarget.1974.CrossRefPubMedPubMedCentral

Lan, F., Yu, H., Hu, M., Xia, T., & Yue, X. (2015). miR-144-3p exerts anti-tumor effects in glioblastoma by targeting c-Met. Journal of Neurochemistry, 135(2), 274–286. https://doi.org/10.1111/jnc.13272.CrossRefPubMed

Lan, X., Jorg, D. J., Cavalli, F. M. G., Richards, L. M., Nguyen, L. V., Vanner, R. J., et al. (2017). Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy. Nature, 549(7671), 227–232. https://doi.org/10.1038/nature23666.CrossRefPubMedPubMedCentral

Lang, F. M., Hossain, A., Gumin, J., Momin, E. N., Shimizu, Y., Ledbetter, D., et al. (2018). Mesenchymal stem cells as natural biofactories for exosomes carrying miR-124a in the treatment of gliomas. Neuro-Oncology, 20(3), 380–390. https://doi.org/10.1093/neuonc/nox152.CrossRefPubMed

Lee, H. J., Lee, W. K., Kang, C. W., Ku, C. R., Cho, Y. H., & Lee, E. J. (2018). A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer. Cancer Letters, 417, 131–140. https://doi.org/10.1016/j.canlet.2017.12.037.CrossRefPubMed

Legg, J. A., Herbert, J. M., Clissold, P., & Bicknell, R. (2008). Slits and Roundabouts in cancer, tumour angiogenesis and endothelial cell migration. Angiogenesis, 11(1), 13–21. https://doi.org/10.1007/s10456-008-9100-x.CrossRefPubMed

Li, H., & Yang, B. B. (2012). Stress response of glioblastoma cells mediated by miR-17-5p targeting PTEN and the passenger strand miR-17-3p targeting MDM2. Oncotarget, 3(12), 1653–1668. https://doi.org/10.18632/oncotarget.810.CrossRefPubMedPubMedCentral

Li, Q., Cheng, Q., Chen, Z., Peng, R., Chen, R., Ma, Z., et al. (2016). MicroRNA-663 inhibits the proliferation, migration and invasion of glioblastoma cells via targeting TGF-beta1. Oncology Reports, 35(2), 1125–1134. https://doi.org/10.3892/or.2015.4432.CrossRefPubMed

Li, R. Y., Chen, L. C., Zhang, H. Y., Du, W. Z., Feng, Y., Wang, H. B., et al. (2013). MiR-139 inhibits Mcl-1 expression and potentiates TMZ-induced apoptosis in glioma. CNS Neuroscience & Therapeutics, 19(7), 477–483. https://doi.org/10.1111/cns.12089.CrossRef

Li, W., & Graeber, M. B. (2012). The molecular profile of microglia under the influence of glioma. Neuro-Oncology, 14(8), 958–978. https://doi.org/10.1093/neuonc/nos116.CrossRefPubMedPubMedCentral

Li, W., Guo, F., Wang, P., Hong, S., & Zhang, C. (2014). miR-221/222 confers radioresistance in glioblastoma cells through activating Akt independent of PTEN status. Current Molecular Medicine, 14(1), 185–195.CrossRef

Li, X., Gong, X., Chen, J., Zhang, J., Sun, J., & Guo, M. (2015a). miR-340 inhibits glioblastoma cell proliferation by suppressing CDK6, cyclin-D1 and cyclin-D2. Biochemical and Biophysical Research Communications, 460(3), 670–677. https://doi.org/10.1016/j.bbrc.2015.03.088.CrossRefPubMed

Li, X., Liu, Y., Granberg, K. J., Wang, Q., Moore, L. M., Ji, P., et al. (2015b). Two mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastoma. Oncogene, 34(13), 1619–1628. https://doi.org/10.1038/onc.2014.98.CrossRefPubMed

Li, X. T., Wang, H. Z., Wu, Z. W., Yang, T. Q., Zhao, Z. H., Chen, G. L., et al. (2015). miR-494-3p regulates cellular proliferation, invasion, migration, and apoptosis by PTEN/AKT signaling in human glioblastoma cells. Cellular and Molecular Neurobiology, 35(5), 679–687. https://doi.org/10.1007/s10571-015-0163-0.CrossRefPubMedPubMedCentral

Li, Y., Guessous, F., Zhang, Y., Dipierro, C., Kefas, B., Johnson, E., et al. (2009a). MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Research, 69(19), 7569–7576. https://doi.org/10.1158/0008-5472.CAN-09-0529.CrossRefPubMedPubMedCentral

Li, Y., Li, Y., Ge, P., & Ma, C. (2017). MiR-126 regulates the ERK pathway via targeting KRAS to inhibit the glioma cell proliferation and invasion. Molecular Neurobiology, 54(1), 137–145. https://doi.org/10.1007/s12035-015-9654-8.CrossRefPubMed

Li, Z., Bao, S., Wu, Q., Wang, H., Eyler, C., Sathornsumetee, S., et al. (2009b). Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell, 15(6), 501–513. https://doi.org/10.1016/j.ccr.2009.03.018.CrossRefPubMedPubMedCentral

Liang, J., Cao, R., Zhang, Y., Xia, Y., Zheng, Y., Li, X., et al. (2016). PKM2 dephosphorylation by Cdc25A promotes the Warburg effect and tumorigenesis. Nature Communication, 7, 12431. https://doi.org/10.1038/ncomms12431.CrossRef

Liao, H., Bai, Y., Qiu, S., Zheng, L., Huang, L., Liu, T., et al. (2015). MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2. Oncotarget, 6(11), 8914–8928. https://doi.org/10.18632/oncotarget.3563.CrossRefPubMedPubMedCentral

Liebelt, B. D., Shingu, T., Zhou, X., Ren, J., Shin, S. A., & Hu, J. (2016). Glioma stem cells: Signaling, microenvironment, and therapy. Stem Cells International, 2016, 7849890. https://doi.org/10.1155/2016/7849890.CrossRefPubMedPubMedCentral

Lin, A. Y., Chua, M. S., Choi, Y. L., Yeh, W., Kim, Y. H., Azzi, R., et al. (2011). Comparative profiling of primary colorectal carcinomas and liver metastases identifies LEF1 as a prognostic biomarker. PLoS ONE, 6(2), e16636. https://doi.org/10.1371/journal.pone.0016636.CrossRefPubMedPubMedCentral

Lin, H. Y., Wang, X. F., Ng-Eaton, E., Weinberg, R. A., & Lodish, H. F. (1992). Expression cloning of the TGF-beta type II receptor, a functional transmembrane serine/threonine kinase. Cell, 68(4), 775–785.CrossRef

Lin, J., Teo, S., Lam, D. H., Jeyaseelan, K., & Wang, S. (2012). MicroRNA-10b pleiotropically regulates invasion, angiogenicity and apoptosis of tumor cells resembling mesenchymal subtype of glioblastoma multiforme. Cell Death & Disease, 3, e398. https://doi.org/10.1038/cddis.2012.134.CrossRef

Liu, J., Xu, J., Li, H., Sun, C., Yu, L., Li, Y., et al. (2015). miR-146b-5p functions as a tumor suppressor by targeting TRAF6 and predicts the prognosis of human gliomas. Oncotarget, 6(30), 29129–29142. https://doi.org/10.18632/oncotarget.4895.CrossRefPubMedPubMedCentral

Liu, S., Sun, J., & Lan, Q. (2013). TGF-beta-induced miR10a/b expression promotes human glioma cell migration by targeting PTEN. Molecular Medicine Reports, 8(6), 1741–1746. https://doi.org/10.3892/mmr.2013.1709.CrossRefPubMed

Liu, Y., Yan, W., Zhang, W., Chen, L., You, G., Bao, Z., et al. (2012). MiR-218 reverses high invasiveness of glioblastoma cells by targeting the oncogenic transcription factor LEF1. Oncology Reports, 28(3), 1013–1021. https://doi.org/10.3892/or.2012.1902.CrossRefPubMed

Liu, Y. S., Lin, H. Y., Lai, S. W., Huang, C. Y., Huang, B. R., Chen, P. Y., et al. (2017). MiR-181b modulates EGFR-dependent VCAM-1 expression and monocyte adhesion in glioblastoma. Oncogene, 36(35), 5006–5022. https://doi.org/10.1038/onc.2017.129.CrossRefPubMed

Liu, Z., Jiang, Z., Huang, J., Huang, S., Li, Y., Yu, S., et al. (2014). miR-7 inhibits glioblastoma growth by simultaneously interfering with the PI3K/ATK and Raf/MEK/ERK pathways. International Journal of Oncology, 44(5), 1571–1580. https://doi.org/10.3892/ijo.2014.2322.CrossRefPubMed

Louis, D. N., Perry, A., Reifenberger, G., von Deimling, A., Figarella-Branger, D., Cavenee, W. K., et al. (2016). The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathologica, 131(6), 803–820. https://doi.org/10.1007/s00401-016-1545-1.CrossRefPubMed

Luan, W., Wang, Y., Chen, X., Shi, Y., Wang, J., Zhang, J., et al. (2015). PKM2 promotes glucose metabolism and cell growth in gliomas through a mechanism involving a let-7a/c-Myc/hnRNPA1 feedback loop. Oncotarget, 6(15), 13006–13018. https://doi.org/10.18632/oncotarget.3514.CrossRefPubMedPubMedCentral

Lv, C., Li, F., Li, X., Tian, Y., Zhang, Y., Sheng, X., et al. (2017). MiR-31 promotes mammary stem cell expansion and breast tumorigenesis by suppressing Wnt signaling antagonists. Nature Communications, 8(1), 1036. https://doi.org/10.1038/s41467-017-01059-5.CrossRefPubMedPubMedCentral

Ma, J., Yao, Y., Wang, P., Liu, Y., Zhao, L., Li, Z., et al. (2014). MiR-152 functions as a tumor suppressor in glioblastoma stem cells by targeting Kruppel-like factor 4. Cancer Letters, 355(1), 85–95. https://doi.org/10.1016/j.canlet.2014.09.012.CrossRefPubMed

Marrero-Rodriguez, D., la Cruz, H. A., Taniguchi-Ponciano, K., Gomez-Virgilio, L., Huerta-Padilla, V., Ponce-Navarrete, G., et al. (2017). Kruppel like factors family expression in cervical cancer cells. Archives of Medical Research, 48(4), 314–322. https://doi.org/10.1016/j.arcmed.2017.06.011.CrossRefPubMed

Massague, J. (2012). TGFbeta signalling in context. Nature Reviews Molecular Cell Biology, 13(10), 616–630. https://doi.org/10.1038/nrm3434.CrossRefPubMedPubMedCentral

Mathew, L. K., Huangyang, P., Mucaj, V., Lee, S. S., Skuli, N., Eisinger-Mathason, T. S., et al. (2015). Feedback circuitry between miR-218 repression and RTK activation in glioblastoma. Science Signaling, 8(375), ra42. https://doi.org/10.1126/scisignal.2005978.CrossRefPubMedPubMedCentral

Mathew, L. K., Skuli, N., Mucaj, V., Lee, S. S., Zinn, P. O., Sathyan, P., et al. (2014). miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma. Proceedings of the National Academy of Sciences USA, 111(1), 291–296. https://doi.org/10.1073/pnas.1314341111.CrossRef

Meneses, A. M., Medina, R. A., Kato, S., Pinto, M., Jaque, M. P., Lizama, I., et al. (2008). Regulation of GLUT3 and glucose uptake by the cAMP signalling pathway in the breast cancer cell line ZR-75. Journal of Cellular Physiology, 214(1), 110–116. https://doi.org/10.1002/jcp.21166.CrossRefPubMed

Miele, L., Miao, H., & Nickoloff, B. J. (2006). NOTCH signaling as a novel cancer therapeutic target. Current Cancer Drug Targets, 6(4), 313–323.CrossRef

Miettinen, P. J., Ebner, R., Lopez, A. R., & Derynck, R. (1994). TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: Involvement of type I receptors. The Journal of Cell Biology, 127(6 Pt 2), 2021–2036.CrossRef

Miroshnikova, Y. A., Mouw, J. K., Barnes, J. M., Pickup, M. W., Lakins, J. N., Kim, Y., et al. (2016). Tissue mechanics promote IDH1-dependent HIF1alpha-tenascin C feedback to regulate glioblastoma aggression. Nature Cell Biology, 18(12), 1336–1345. https://doi.org/10.1038/ncb3429.CrossRefPubMedPubMedCentral

Montor, W. R., Salas, A., & Melo, F. H. M. (2018). Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: The current arsenal of inhibitors. Molecular Cancer, 17(1), 55. https://doi.org/10.1186/s12943-018-0792-2.CrossRefPubMedPubMedCentral

Movila, A., Ishii, T., Albassam, A., Wisitrasameewong, W., Howait, M., Yamaguchi, T., et al. (2016). Macrophage migration inhibitory factor (MIF) supports homing of osteoclast precursors to peripheral osteolytic lesions. Journal of Bone and Mineral Research, 31(9), 1688–1700. https://doi.org/10.1002/jbmr.2854.CrossRefPubMedPubMedCentral

Munoz, J. L., Bliss, S. A., Greco, S. J., Ramkissoon, S. H., Ligon, K. L., & Rameshwar, P. (2013). Delivery of functional anti-miR-9 by mesenchymal stem cell-derived exosomes to glioblastoma multiforme cells conferred chemosensitivity. Molecular Therapy - Nucleic Acids, 2, e126. https://doi.org/10.1038/mtna.2013.60.CrossRefPubMedPubMedCentral

Ng, W. L., Yan, D., Zhang, X., Mo, Y. Y., & Wang, Y. (2010). Over-expression of miR-100 is responsible for the low-expression of ATM in the human glioma cell line: M059J. DNA Repair, 9(11), 1170–1175. https://doi.org/10.1016/j.dnarep.2010.08.007.CrossRefPubMedPubMedCentral

Nie, E., Jin, X., Wu, W., Yu, T., Zhou, X., Shi, Z., et al. (2017). MiR-198 enhances temozolomide sensitivity in glioblastoma by targeting MGMT. Journal of Neuro-Oncology, 133(1), 59–68. https://doi.org/10.1007/s11060-017-2425-9.CrossRefPubMed

Nishikawa, H., & Sakaguchi, S. (2010). Regulatory T cells in tumor immunity. International Journal of Cancer, 127(4), 759–767. https://doi.org/10.1002/ijc.25429.CrossRefPubMed

Niu, H., Wang, K., Zhang, A., Yang, S., Song, Z., Wang, W., et al. (2012). miR-92a is a critical regulator of the apoptosis pathway in glioblastoma with inverse expression of BCL2L11. Oncology Reports, 28(5), 1771–1777. https://doi.org/10.3892/or.2012.1970.CrossRefPubMed

Oft, M., Peli, J., Rudaz, C., Schwarz, H., Beug, H., & Reichmann, E. (1996). TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes & Development, 10(19), 2462–2477.CrossRef

Oh, B., Song, H., Lee, D., Oh, J., Kim, G., Ihm, S. H., et al. (2017). Anti-cancer effect of R3V6 peptide-mediated delivery of an anti-microRNA-21 antisense-oligodeoxynucleotide in a glioblastoma animal model. Journal of Drug Targeting, 25(2), 132–139. https://doi.org/10.1080/1061186X.2016.1207648.CrossRefPubMed

Orouji, E., Orouji, A., Gaiser, T., Larribere, L., Gebhardt, C., & Utikal, J. (2016). MAP kinase pathway gene copy alterations in NRAS/BRAF wild-type advanced melanoma. International Journal of Cancer, 138(9), 2257–2262. https://doi.org/10.1002/ijc.29970.CrossRefPubMed

Ouyang, Q., Chen, G., Zhou, J., Li, L., Dong, Z., Yang, R., et al. (2016). Neurotensin signaling stimulates glioblastoma cell proliferation by upregulating c-Myc and inhibiting miR-29b-1 and miR-129-3p. Neuro-Oncology, 18(2), 216–226. https://doi.org/10.1093/neuonc/nov114.CrossRefPubMed

Pang, H., Zheng, Y., Zhao, Y., Xiu, X., & Wang, J. (2015). miR-590-3p suppresses cancer cell migration, invasion and epithelial-mesenchymal transition in glioblastoma multiforme by targeting ZEB1 and ZEB2. Biochemical and Biophysical Research Communications, 468(4), 739–745. https://doi.org/10.1016/j.bbrc.2015.11.025.CrossRefPubMed

Papagiannakopoulos, T., Friedmann-Morvinski, D., Neveu, P., Dugas, J. C., Gill, R. M., Huillard, E., et al. (2012). Pro-neural miR-128 is a glioma tumor suppressor that targets mitogenic kinases. Oncogene, 31(15), 1884–1895. https://doi.org/10.1038/onc.2011.380.CrossRefPubMed

Perera, M., Tsang, C. S., Distel, R. J., Lacy, J. N., Ohno-Machado, L., Ricchiuti, V., et al. (2010). TGF-beta1 interactome: Metastasis and beyond. Cancer Genomics & Proteomics, 7(4), 217–229.

Perry, J. R., Laperriere, N., O’Callaghan, C. J., Brandes, A. A., Menten, J., Phillips, C., et al. (2017). Short-course radiation plus temozolomide in elderly patients with glioblastoma. The New England Journal of Medicine, 376(11), 1027–1037. https://doi.org/10.1056/NEJMoa1611977.CrossRefPubMed

Phan, L. M., Yeung, S. C., & Lee, M. H. (2014). Cancer metabolic reprogramming: Importance, main features, and potentials for precise targeted anti-cancer therapies. Cancer Biology & Medicine, 11(1), 1–19. https://doi.org/10.7497/j.issn.2095-3941.2014.01.001.CrossRef

Phillips, H. S., Kharbanda, S., Chen, R., Forrest, W. F., Soriano, R. H., Wu, T. D., et al. (2006). Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell, 9(3), 157–173. https://doi.org/10.1016/j.ccr.2006.02.019.CrossRefPubMed

Ping, Y. F., Yao, X. H., Jiang, J. Y., Zhao, L. T., Yu, S. C., Jiang, T., et al. (2011). The chemokine CXCL12 and its receptor CXCR4 promote glioma stem cell-mediated VEGF production and tumour angiogenesis via PI3K/AKT signalling. The Journal of Pathology, 224(3), 344–354. https://doi.org/10.1002/path.2908.CrossRefPubMed

Poi, M. J., Knobloch, T. J., & Li, J. (2017). Deletion of RD (INK4/ARF) enhancer: A novel mutation to “inactivate” the INK4-ARF locus. DNA Repair, 57, 50–55. https://doi.org/10.1016/j.dnarep.2017.06.027.CrossRefPubMed

Qi, X. C., Xie, D. J., Yan, Q. F., Wang, Y. R., Zhu, Y. X., Qian, C., et al. (2013). LRIG1 dictates the chemo-sensitivity of temozolomide (TMZ) in U251 glioblastoma cells via down-regulation of EGFR/topoisomerase-2/Bcl-2. Biochemical and Biophysical Research Communications, 437(4), 565–572. https://doi.org/10.1016/j.bbrc.2013.06.116.CrossRefPubMed

Qian, X., Wang, X., & Jin, H. (2014). Cell transfer therapy for cancer: Past, present, and future. Journal of Immunology Research, 2014, 525913. https://doi.org/10.1155/2014/525913.CrossRefPubMedPubMedCentral

Qiang, L., Wu, T., Zhang, H. W., Lu, N., Hu, R., Wang, Y. J., et al. (2012). HIF-1alpha is critical for hypoxia-mediated maintenance of glioblastoma stem cells by activating Notch signaling pathway. Cell Death & Differentiation, 19(2), 284–294. https://doi.org/10.1038/cdd.2011.95.CrossRef

Qiu, S., Huang, D., Yin, D., Li, F., Li, X., Kung, H. F., et al. (2013). Suppression of tumorigenicity by microRNA-138 through inhibition of EZH2-CDK4/6-pRb-E2F1 signal loop in glioblastoma multiforme. Biochimica et Biophysica Acta, 1832(10), 1697–1707. https://doi.org/10.1016/j.bbadis.2013.05.015.CrossRefPubMed

Quintavalle, C., Donnarumma, E., Iaboni, M., Roscigno, G., Garofalo, M., Romano, G., et al. (2013). Effect of miR-21 and miR-30b/c on TRAIL-induced apoptosis in glioma cells. Oncogene, 32(34), 4001–4008. https://doi.org/10.1038/onc.2012.410.CrossRefPubMed

Rajbhandari, R., McFarland, B. C., Patel, A., Gerigk, M., Gray, G. K., Fehling, S. C., et al. (2015). Loss of tumor suppressive microRNA-31 enhances TRADD/NF-kappaB signaling in glioblastoma. Oncotarget, 6(19), 17805–17816. https://doi.org/10.18632/oncotarget.4596.CrossRefPubMedPubMedCentral

Ramakrishnan, A. B., Sinha, A., Fan, V. B., & Cadigan, K. M. (2018). The Wnt transcriptional switch: TLE removal or inactivation? Bioessays. https://doi.org/10.1002/bies.201700162.CrossRefPubMed

Rani, S. B., Rathod, S. S., Karthik, S., Kaur, N., Muzumdar, D., & Shiras, A. S. (2013). MiR-145 functions as a tumor-suppressive RNA by targeting Sox9 and adducin 3 in human glioma cells. Neuro-Oncology, 15(10), 1302–1316. https://doi.org/10.1093/neuonc/not090.CrossRefPubMedPubMedCentral

Rao, S. A., Arimappamagan, A., Pandey, P., Santosh, V., Hegde, A. S., Chandramouli, B. A., et al. (2013). miR-219-5p inhibits receptor tyrosine kinase pathway by targeting EGFR in glioblastoma. PLoS ONE, 8(5), e63164. https://doi.org/10.1371/journal.pone.0063164.CrossRefPubMedPubMedCentral

Rathod, S. S., Rani, S. B., Khan, M., Muzumdar, D., & Shiras, A. (2014). Tumor suppressive miRNA-34a suppresses cell proliferation and tumor growth of glioma stem cells by targeting Akt and Wnt signaling pathways. FEBS Open Bio, 4, 485–495. https://doi.org/10.1016/j.fob.2014.05.002.CrossRefPubMedPubMedCentral

Resnitzky, D., Gossen, M., Bujard, H., & Reed, S. I. (1994). Acceleration of the G1/S phase transition by expression of cyclins D1 and E with an inducible system. Journal of Molecular Cell Biology, 14(3), 1669–1679.CrossRef

Rodriguez, M., Bajo-Santos, C., Hessvik, N. P., Lorenz, S., Fromm, B., Berge, V., et al. (2017). Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes. Molecular Cancer, 16(1), 156. https://doi.org/10.1186/s12943-017-0726-4.CrossRefPubMedPubMedCentral

Rossowska, J., Anger, N., Szczygiel, A., Mierzejewska, J., & Pajtasz-Piasecka, E. (2017). Intratumoral lentivector-mediated TGF-beta1 gene downregulation as a potent strategy for enhancing the antitumor effect of therapy composed of cyclophosphamide and dendritic cells. Frontiers in Immunology, 8, 713. https://doi.org/10.3389/fimmu.2017.00713.CrossRefPubMedPubMedCentral

Sahebjam, S., Sharabi, A., Lim, M., Kesarwani, P., & Chinnaiyan, P. (2017). Immunotherapy and radiation in glioblastoma. Journal of Neuro-Oncology, 134(3), 531–539. https://doi.org/10.1007/s11060-017-2413-0.CrossRefPubMed

Sasayama, T., Nishihara, M., Kondoh, T., Hosoda, K., & Kohmura, E. (2009). MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. International Journal of Cancer, 125(6), 1407–1413. https://doi.org/10.1002/ijc.24522.CrossRefPubMed

Sato, H., & Seiki, M. (1993). Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene, 8(2), 395–405.PubMed

Schmetterer, K. G., & Pickl, W. F. (2017). The IL-10/STAT3 axis: Contributions to immune tolerance by thymus and peripherally derived regulatory T cells. European Journal of Immunology, 47(8), 1256–1265. https://doi.org/10.1002/eji.201646710.CrossRefPubMed

Schmidt, M., & Ache, B. W. (1997). Immunocytochemical analysis of glomerular regionalization and neuronal diversity in the olfactory deutocerebrum of the spiny lobster. Cell and Tissue Research, 287(3), 541–563.CrossRef

Serrano, M., Hannon, G. J., & Beach, D. (1993). A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature, 366(6456), 704–707. https://doi.org/10.1038/366704a0.CrossRefPubMed

Shang, C., Guo, Y., Hong, Y., Liu, Y. H., & Xue, Y. X. (2015). MiR-21 up-regulation mediates glioblastoma cancer stem cells apoptosis and proliferation by targeting FASLG. Molecular Biology Reports, 42(3), 721–727. https://doi.org/10.1007/s11033-014-3820-3.CrossRefPubMed

Shen, K., Ji, L., Gong, C., Ma, Y., Yang, L., Fan, Y., et al. (2012). Notoginsenoside Ft1 promotes angiogenesis via HIF-1alpha mediated VEGF secretion and the regulation of PI3K/AKT and Raf/MEK/ERK signaling pathways. Biochemical Pharmacology, 84(6), 784–792. https://doi.org/10.1016/j.bcp.2012.05.024.CrossRefPubMed

Shen, L., Sun, C., Li, Y., Li, X., Sun, T., Liu, C., et al. (2015). MicroRNA-199a-3p suppresses glioma cell proliferation by regulating the AKT/mTOR signaling pathway. Tumour Biology, 36(9), 6929–6938. https://doi.org/10.1007/s13277-015-3409-z.CrossRefPubMedPubMedCentral

Shi, L., Wan, Y., Sun, G., Zhang, S., Wang, Z., & Zeng, Y. (2014a). miR-125b inhibitor may enhance the invasion-prevention activity of temozolomide in glioblastoma stem cells by targeting PIAS3. BioDrugs, 28(1), 41–54, https://doi.org/10.1007/s40259-013-0053-2.CrossRefPubMed

Shi, Y., Chen, C., Yu, S. Z., Liu, Q., Rao, J., Zhang, H. R., et al. (2015). miR-663 suppresses oncogenic function of CXCR4 in glioblastoma. Clinical Cancer Research, 21(17), 4004–4013. https://doi.org/10.1158/1078-0432.CCR-14-2807.CrossRefPubMed

Shi, Z., Chen, Q., Li, C., Wang, L., Qian, X., Jiang, C., et al. (2014b). MiR-124 governs glioma growth and angiogenesis and enhances chemosensitivity by targeting R-Ras and N-Ras. Neuro-Oncology, 16(10), 1341–1353. https://doi.org/10.1093/neuonc/nou084.CrossRefPubMedPubMedCentral

Shi, Z. M., Wang, J., Yan, Z., You, Y. P., Li, C. Y., Qian, X., et al. (2012). MiR-128 inhibits tumor growth and angiogenesis by targeting p70S6K1. PLoS ONE, 7(3), e32709. https://doi.org/10.1371/journal.pone.0032709.CrossRefPubMedPubMedCentral

Shuman Moss, L. A., Jensen-Taubman, S., & Stetler-Stevenson, W. G. (2012). Matrix metalloproteinases: Changing roles in tumor progression and metastasis. American Journal of Pathology, 181(6), 1895–1899. https://doi.org/10.1016/j.ajpath.2012.08.044.CrossRefPubMed

Smits, M., Wurdinger, T., van het Hof, B., Drexhage, J. A., Geerts, D., Wesseling, P., et al. (2012). Myc-associated zinc finger protein (MAZ) is regulated by miR-125b and mediates VEGF-induced angiogenesis in glioblastoma. FASEB Journal, 26(6), 2639–2647. https://doi.org/10.1096/fj.11-202820.CrossRefPubMed

Soeda, A., Park, M., Lee, D., Mintz, A., Androutsellis-Theotokis, A., McKay, R. D., et al. (2009). Hypoxia promotes expansion of the CD133-positive glioma stem cells through activation of HIF-1alpha. Oncogene, 28(45), 3949–3959. https://doi.org/10.1038/onc.2009.252.CrossRefPubMed

Song, Y., Chen, Y., Li, Y., Lyu, X., Cui, J., Cheng, Y., et al. (2018). Metformin inhibits TGF-beta1-induced epithelial-to-mesenchymal transition-like process and stem-like properties in GBM via AKT/mTOR/ZEB1 pathway. Oncotarget, 9(6), 7023–7035. https://doi.org/10.18632/oncotarget.23317.CrossRefPubMed

Srinivasan, S., Patric, I. R., & Somasundaram, K. (2011). A ten-microRNA expression signature predicts survival in glioblastoma. PLoS ONE, 6(3), e17438. https://doi.org/10.1371/journal.pone.0017438.CrossRefPubMedPubMedCentral

Stojcheva, N., Schechtmann, G., Sass, S., Roth, P., Florea, A. M., Stefanski, A., et al. (2016). MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM. Oncotarget, 7(11), 12937–12950. https://doi.org/10.18632/oncotarget.7346.CrossRefPubMedPubMedCentral

Strobele, S., Schneider, M., Schneele, L., Siegelin, M. D., Nonnenmacher, L., Zhou, S., et al. (2015). A potential role for the inhibition of PI3K signaling in glioblastoma therapy. PLoS ONE, 10(6), e0131670. https://doi.org/10.1371/journal.pone.0131670.CrossRefPubMedPubMedCentral

Suh, S. S., Yoo, J. Y., Nuovo, G. J., Jeon, Y. J., Kim, S., Lee, T. J., et al. (2012). MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme. Proceedings of the National Academy of Sciences of the United States of America, 109(14), 5316–5321. https://doi.org/10.1073/pnas.1202465109.CrossRefPubMedPubMedCentral

Sulman, E. P., Ismaila, N., Armstrong, T. S., Tsien, C., Batchelor, T. T., Cloughesy, T., et al. (2017a). Radiation therapy for glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. Journal of Clinical Oncology, 35(3), 361–369. https://doi.org/10.1200/JCO.2016.70.7562.CrossRefPubMed

Sulman, E. P., Ismaila, N., & Chang, S. M. (2017b). Radiation therapy for glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. Journal of Oncology Practice, 13(2), 123–127. https://doi.org/10.1200/JOP.2016.018937.CrossRefPubMed

Sumazin, P., Yang, X., Chiu, H. S., Chung, W. J., Iyer, A., Llobet-Navas, D., et al. (2011). An extensive microRNA-mediated network of RNA-RNA interactions regulates established oncogenic pathways in glioblastoma. Cell, 147(2), 370–381. https://doi.org/10.1016/j.cell.2011.09.041.CrossRefPubMedPubMedCentral

Sun, F., Fu, H., Liu, Q., Tie, Y., Zhu, J., Xing, R., et al. (2008). Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Letters, 582(10), 1564–1568. https://doi.org/10.1016/j.febslet.2008.03.057.CrossRefPubMed

Sun, G., Shi, L., Yan, S., Wan, Z., Jiang, N., Fu, L., et al. (2014a). MiR-15b targets cyclin D1 to regulate proliferation and apoptosis in glioma cells. BioMed Research International, 2014, 687826. https://doi.org/10.1155/2014/687826.CrossRefPubMedPubMedCentral

Sun, J. Y., Xiao, W. Z., Wang, F., Wang, Y. Q., Zhu, Y. H., Wu, Y. F., et al. (2015). MicroRNA-320 inhibits cell proliferation in glioma by targeting E2F1. Molecular Medicine Reports, 12(2), 2355–2359. https://doi.org/10.3892/mmr.2015.3657.CrossRefPubMed

Sun, L., Yan, W., Wang, Y., Sun, G., Luo, H., Zhang, J., et al. (2011). MicroRNA-10b induces glioma cell invasion by modulating MMP-14 and uPAR expression via HOXD10. Brain Research, 1389, 9–18. https://doi.org/10.1016/j.brainres.2011.03.013.CrossRefPubMed

Sun, Y. C., Wang, J., Guo, C. C., Sai, K., Wang, J., Chen, F. R., et al. (2014b). MiR-181b sensitizes glioma cells to teniposide by targeting MDM2. BMC Cancer, 14, 611. https://doi.org/10.1186/1471-2407-14-611.CrossRefPubMedPubMedCentral

Syed, V., Zhang, X., Lau, K. M., Cheng, R., Mukherjee, K., & Ho, S. M. (2005). Profiling estrogen-regulated gene expression changes in normal and malignant human ovarian surface epithelial cells. Oncogene, 24(55), 8128–8143. https://doi.org/10.1038/sj.onc.1208959.CrossRefPubMed

Tabatabaei, P., Bergstrom, P., Henriksson, R., & Bergenheim, A. T. (2008). Glucose metabolites, glutamate and glycerol in malignant glioma tumours during radiotherapy. Journal of Neuro-Oncology, 90(1), 35–39. https://doi.org/10.1007/s11060-008-9625-2.CrossRefPubMed

Takenaka, K., Ishikawa, S., Kawano, Y., Yanagihara, K., Miyahara, R., Otake, Y., et al. (2004). Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer. European Journal of Cance, 40(10), 1617–1623. https://doi.org/10.1016/j.ejca.2004.02.028.CrossRef

Tan, X., Wang, S., Yang, B., Zhu, L., Yin, B., Chao, T., et al. (2012a). The CREB-miR-9 negative feedback minicircuitry coordinates the migration and proliferation of glioma cells. PLoS ONE, 7(11), e49570. https://doi.org/10.1371/journal.pone.0049570.CrossRefPubMedPubMedCentral

Tan, X., Wang, S., Zhu, L., Wu, C., Yin, B., Zhao, J., et al. (2012b). cAMP response element-binding protein promotes gliomagenesis by modulating the expression of oncogenic microRNA-23a. Proceedings of the National Academy of Sciences of the United States of America, 109(39), 15805–15810. https://doi.org/10.1073/pnas.1207787109.CrossRefPubMedPubMedCentral

Tang, B., Wu, W., Wei, X., Li, Y., Ren, G., & Fan, W. (2014). Activation of glioma cells generates immune tolerant NKT cells. The Journal of Biological Chemistry, 289(50), 34595–34600. https://doi.org/10.1074/jbc.M114.614503.CrossRefPubMedPubMedCentral

Thiery, J. P. (2002). Epithelial-mesenchymal transitions in tumour progression. Nature Reviews Cancer, 2(6), 442–454. https://doi.org/10.1038/nrc822.CrossRefPubMed

Tian, T., Mingyi, M., Qiu, X., & Qiu, Y. (2016). MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3beta in glioblastoma. Oncotarget, 7(48), 79584–79595. https://doi.org/10.18632/oncotarget.12861.CrossRefPubMedPubMedCentral

Tu, E., Chia, P. Z., & Chen, W. (2014). TGFbeta in T cell biology and tumor immunity: Angel or devil? Cytokine & Growth Factor Reviews, 25(4), 423–435. https://doi.org/10.1016/j.cytogfr.2014.07.014.CrossRef

Ullrich, E., Koch, J., Cerwenka, A., & Steinle, A. (2013). New prospects on the NKG2D/NKG2DL system for oncology. Oncoimmunology, 2(10), e26097. https://doi.org/10.4161/onci.26097.CrossRefPubMedPubMedCentral

van den Bent, M. J., Hegi, M. E., & Stupp, R. (2006). Recent developments in the use of chemotherapy in brain tumours. European Journal of Cancer, 42(5), 582–588. https://doi.org/10.1016/j.ejca.2005.06.031.CrossRefPubMed

Verhaak, R. G., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., et al. (2010). Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 17(1), 98–110. https://doi.org/10.1016/j.ccr.2009.12.020.CrossRefPubMedPubMedCentral

Vieira, G. C., Chockalingam, S., Melegh, Z., Greenhough, A., Malik, S., Szemes, M., et al. (2015). LGR5 regulates pro-survival MEK/ERK and proliferative Wnt/beta-catenin signalling in neuroblastoma. Oncotarget, 6(37), 40053–40067. https://doi.org/10.18632/oncotarget.5548.CrossRefPubMedPubMedCentral

Wang, C., Liu, X., Huang, H., Ma, H., Cai, W., Hou, J., et al. (2012). Deregulation of Snai2 is associated with metastasis and poor prognosis in tongue squamous cell carcinoma. International Journal of Cancer, 130(10), 2249–2258. https://doi.org/10.1002/ijc.26226.CrossRefPubMed

Wang, C., Xiang, R., Zhang, X., & Chen, Y. (2015a). Doxycycline inhibits leukemic cell migration via inhibition of matrix metalloproteinases and phosphorylation of focal adhesion kinase. Molecular Medicine Reports, 12(3), 3374–3380. https://doi.org/10.3892/mmr.2015.3833.CrossRefPubMedPubMedCentral

Wang, E., Wang, D., Li, B., Ma, H., Wang, C., Guan, L., et al. (2017a). Capn4 promotes epithelial-mesenchymal transition in human melanoma cells through activation of the Wnt/beta-catenin pathway. Oncology Reports, 37(1), 379–387. https://doi.org/10.3892/or.2016.5247.CrossRefPubMed

Wang, H., Zhi, H., Ma, D., & Li, T. (2017b). MiR-217 promoted the proliferation and invasion of glioblastoma by repressing YWHAG. Cytokine, 92, 93–102. https://doi.org/10.1016/j.cyto.2016.12.013.CrossRefPubMed

Wang, J., Sai, K., Chen, F. R., & Chen, Z. P. (2013a). miR-181b modulates glioma cell sensitivity to temozolomide by targeting MEK1. Cancer Chemotherapy and Pharmacology, 72(1), 147–158. https://doi.org/10.1007/s00280-013-2180-3.CrossRefPubMed

Wang, L., Shi, Z. M., Jiang, C. F., Liu, X., Chen, Q. D., Qian, X., et al. (2014). MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-induced apoptosis in glioma. Oncotarget, 5(14), 5416–5427. https://doi.org/10.18632/oncotarget.2116.CrossRefPubMedPubMedCentral

Wang, L., Zhang, J., Banerjee, S., Barnes, L., Barnes, L., Sajja, V., et al. (2010a). Sumoylation of vimentin354 is associated with PIAS3 inhibition of glioma cell migration. Oncotarget, 1(7), 620–627. https://doi.org/10.18632/oncotarget.101101.CrossRefPubMedPubMedCentral

Wang, S. S., Feng, L., Hu, B. G., Lu, Y. F., Wang, W. M., Guo, W., et al. (2017c). miR-133a promotes TRAIL resistance in glioblastoma via suppressing death receptor 5 and activating NF-kappaB signaling. Molecular Therapy - Nucleic Acids, 8, 482–492. https://doi.org/10.1016/j.omtn.2017.07.015.CrossRefPubMedPubMedCentral

Wang, X., Xin, Z., Xu, Y., & Ma, J. (2016a). Upregulated miRNA-622 inhibited cell proliferation, motility, and invasion via repressing Kirsten rat sarcoma in glioblastoma. Tumour Biology, 37(5), 5963–5970. https://doi.org/10.1007/s13277-015-4455-2.CrossRefPubMed

Wang, X. R., Luo, H., Li, H. L., Cao, L., Wang, X. F., Yan, W., et al. (2013b). Overexpressed let-7a inhibits glioma cell malignancy by directly targeting K-ras, independently of PTEN. Neuro-Oncology, 15(11), 1491–1501. https://doi.org/10.1093/neuonc/not107.CrossRefPubMedPubMedCentral

Wang, Z., Li, Y., Kong, D., Ahmad, A., Banerjee, S., & Sarkar, F. H. (2010b). Cross-talk between miRNA and Notch signaling pathways in tumor development and progression. Cancer Letters, 292(2), 141–148. https://doi.org/10.1016/j.canlet.2009.11.012.CrossRefPubMed

Wang, Z., Wang, B., Shi, Y., Xu, C., Xiao, H. L., Ma, L. N., et al. (2015b). Oncogenic miR-20a and miR-106a enhance the invasiveness of human glioma stem cells by directly targeting TIMP-2. Oncogene, 34(11), 1407–1419. https://doi.org/10.1038/onc.2014.75.CrossRefPubMed

Wang, Z., Xue, Y., Wang, P., Zhu, J., & Ma, J. (2016b). MiR-608 inhibits the migration and invasion of glioma stem cells by targeting macrophage migration inhibitory factor. Oncology Reports, 35(5), 2733–2742. https://doi.org/10.3892/or.2016.4652.CrossRefPubMed

Wei, F., Wang, Q., Su, Q., Huang, H., Luan, J., Xu, X., et al. (2016a). miR-373 inhibits glioma cell U251 migration and invasion by down-regulating CD44 and TGFBR2. Cellular and Molecular Neurobiology, 36(8), 1389–1397. https://doi.org/10.1007/s10571-016-0338-3.CrossRefPubMed

Wei, J., Nduom, E. K., Kong, L. Y., Hashimoto, Y., Xu, S., Gabrusiewicz, K., et al. (2016b). MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. Neuro-Oncology, 18(5), 639–648. https://doi.org/10.1093/neuonc/nov292.CrossRefPubMed

Wei, J., Qi, X., Zhan, Q., Zhou, D., Yan, Q., Wang, Y., et al. (2015). miR-20a mediates temozolomide-resistance in glioblastoma cells via negatively regulating LRIG1 expression. Biomedicine & Pharmacotherapy, 71, 112–118. https://doi.org/10.1016/j.biopha.2015.01.026.CrossRef

Wei, J., Wang, F., Kong, L. Y., Xu, S., Doucette, T., Ferguson, S. D., et al. (2013). miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. Cancer Research, 73(13), 3913–3926. https://doi.org/10.1158/0008-5472.CAN-12-4318.CrossRefPubMedPubMedCentral

Welch, D. R., Fabra, A., & Nakajima, M. (1990). Transforming growth factor beta stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proceedings of the National Academy of Sciences USA, 87(19), 7678–7682.CrossRef

Wolf, A., Agnihotri, S., & Guha, A. (2010). Targeting metabolic remodeling in glioblastoma multiforme. Oncotarget, 1(7), 552–562. https://doi.org/10.18632/oncotarget.101014.CrossRefPubMedPubMedCentral

Wolf, A., Agnihotri, S., Micallef, J., Mukherjee, J., Sabha, N., Cairns, R., et al. (2011). Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. The Journal of Experimental Medicine, 208(2), 313–326. https://doi.org/10.1084/jem.20101470.CrossRefPubMedPubMedCentral

Wong, H. A., Fatimy, R. E., Onodera, C., Wei, Z., Yi, M., Mohan, A., et al. (2015). The cancer genome atlas analysis predicts microRNA for targeting cancer growth and vascularization in glioblastoma. Molecular Therapy, 23(7), 1234–1247. https://doi.org/10.1038/mt.2015.72.CrossRefPubMedPubMedCentral

Wu, A., Wei, J., Kong, L. Y., Wang, Y., Priebe, W., Qiao, W., et al. (2010). Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro-Oncolgy, 12(11), 1113–1125. https://doi.org/10.1093/neuonc/noq082.CrossRef

Wu, D. G., Wang, Y. Y., Fan, L. G., Luo, H., Han, B., Sun, L. H., et al. (2011). MicroRNA-7 regulates glioblastoma cell invasion via targeting focal adhesion kinase expression. Chinese Medical Journal (English), 124(17), 2616–2621.

Wurdinger, T., Tannous, B. A., Saydam, O., Skog, J., Grau, S., Soutschek, J., et al. (2008). miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell, 14(5), 382–393. https://doi.org/10.1016/j.ccr.2008.10.005.CrossRefPubMedPubMedCentral

Xi, Z., Wang, P., Xue, Y., Shang, C., Liu, X., Ma, J., et al. (2017). Overexpression of miR-29a reduces the oncogenic properties of glioblastoma stem cells by downregulating Quaking gene isoform 6. Oncotarget, 8(15), 24949–24963. https://doi.org/10.18632/oncotarget.15327.CrossRefPubMedPubMedCentral

Xia, X., Li, Y., Wang, W., Tang, F., Tan, J., Sun, L., et al. (2015). MicroRNA-1908 functions as a glioblastoma oncogene by suppressing PTEN tumor suppressor pathway. Molecular Cancer, 14, 154. https://doi.org/10.1186/s12943-015-0423-0.CrossRefPubMedPubMedCentral

Xiao, B., Tan, L., He, B., Liu, Z., & Xu, R. (2013). MiRNA-329 targeting E2F1 inhibits cell proliferation in glioma cells. Journal of Translational Medicine, 11, 172. https://doi.org/10.1186/1479-5876-11-172.CrossRefPubMedPubMedCentral

Xiao, B., Zhou, X., Ye, M., Lv, S., Wu, M., Liao, C., et al. (2016). MicroRNA566 modulates vascular endothelial growth factor by targeting Von HippelLandau in human glioblastoma in vitro and in vivo. Molecular Medicine Reports, 13(1), 379–385. https://doi.org/10.3892/mmr.2015.4537.CrossRefPubMed

Xiao, S., Yang, Z., Lv, R., Zhao, J., Wu, M., Liao, Y., et al. (2014). miR-135b contributes to the radioresistance by targeting GSK3beta in human glioblastoma multiforme cells. PLoS ONE, 9(9), e108810. https://doi.org/10.1371/journal.pone.0108810.CrossRefPubMedPubMedCentral

Xie, J., Burt, D. R., & Gao, G. (2015). Adeno-associated virus-mediated microRNA delivery and therapeutics. Seminars in Liver Disease, 35(1), 81–88. https://doi.org/10.1055/s-0034-1397352.CrossRefPubMedPubMedCentral

Xu, F., Li, F., Zhang, W., & Jia, P. (2015a). Growth of glioblastoma is inhibited by miR-133-mediated EGFR suppression. Tumour Biology, 36(12), 9553–9558. https://doi.org/10.1007/s13277-015-3724-4.CrossRefPubMed

Xu, G., & Shi, Y. (2007). Apoptosis signaling pathways and lymphocyte homeostasis. Cell Research, 17(9), 759–771. https://doi.org/10.1038/cr.2007.52.CrossRefPubMed

Xu, J., Liao, X., Lu, N., Liu, W., & Wong, C. W. (2011). Chromatin-modifying drugs induce miRNA-153 expression to suppress Irs-2 in glioblastoma cell lines. International Journal of Cancer, 129(10), 2527–2531. https://doi.org/10.1002/ijc.25917.CrossRefPubMed

Xu, J., Liao, X., & Wong, C. (2010). Downregulations of B-cell lymphoma 2 and myeloid cell leukemia sequence 1 by microRNA 153 induce apoptosis in a glioblastoma cell line DBTRG-05MG. International Journal of Cancer, 126(4), 1029–1035. https://doi.org/10.1002/ijc.24823.CrossRefPubMed

Xu, T., Jiang, Y., Yan, Y., Wang, H., Lu, C., Xu, H., et al. (2015b). VSIG4 is highly expressed and correlated with poor prognosis of high-grade glioma patients. American Journal of Translational Research, 7(6), 1172–1180.PubMedPubMedCentral

Yamasaki, H., Krutovskikh, V., Mesnil, M., Tanaka, T., Zaidan-Dagli, M. L., & Omori, Y. (1999). Role of connexin (gap junction) genes in cell growth control and carcinogenesis. Comptes Rendus de l’Académie des Sciences - Series III, 322(2–3), 151–159.CrossRef

Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., et al. (2009). IDH1 and IDH2 mutations in gliomas. The New England Journal of Medicine, 360(8), 765–773. https://doi.org/10.1056/NEJMoa0808710.CrossRefPubMedPubMedCentral

Yan, W., Zhang, W., Sun, L., Liu, Y., You, G., Wang, Y., et al. (2011). Identification of MMP-9 specific microRNA expression profile as potential targets of anti-invasion therapy in glioblastoma multiforme. Brain Research, 1411, 108–115. https://doi.org/10.1016/j.brainres.2011.07.002.CrossRefPubMed

Yang, F., Luo, W. J., Sun, W., Wang, Y., Wang, J. L., Yang, F., et al. (2017). SDF1-CXCR4 signaling maintains central post-stroke pain through mediation of glial-neuronal interactions. Frontiers in Molecular Neuroscience, 10, 226. https://doi.org/10.3389/fnmol.2017.00226.CrossRefPubMedPubMedCentral

Yang, T. Q., Lu, X. J., Wu, T. F., Ding, D. D., Zhao, Z. H., Chen, G. L., et al. (2014). MicroRNA-16 inhibits glioma cell growth and invasion through suppression of BCL2 and the nuclear factor-kappaB1/MMP9 signaling pathway. Cancer Science, 105(3), 265–271. https://doi.org/10.1111/cas.12351.CrossRefPubMedPubMedCentral

Yao, Y., Ma, J., Xue, Y., Wang, P., Li, Z., Li, Z., et al. (2015a). MiR-449a exerts tumor-suppressive functions in human glioblastoma by targeting Myc-associated zinc-finger protein. Molecular Oncology, 9(3), 640–656. https://doi.org/10.1016/j.molonc.2014.11.003.CrossRefPubMed

Yao, Y. L., Ma, J., Wang, P., Xue, Y. X., Li, Z., Zhao, L. N., et al. (2015b). miR-101 acts as a tumor suppressor by targeting Kruppel-like factor 6 in glioblastoma stem cells. CNS Neuroscience & Therapeutics, 21(1), 40–51. https://doi.org/10.1111/cns.12321.CrossRef

Yu, X., Zheng, H., Chan, M. T., & Wu, W. K. (2017). Modulation of chemoresponsiveness to platinum-based agents by microRNAs in cancer. American Journal of Cancer Research, 7(9), 1769–1778.PubMedPubMedCentral

Yuan, G. Q., Wei, N. L., Mu, L. Y., Wang, X. Q., Zhang, Y. N., Zhou, W. N., et al. (2017). A 4-miRNAs signature predicts survival in glioblastoma multiforme patients. Cancer Biomarkers, 20(4), 443–452. https://doi.org/10.3233/CBM-170205.CrossRefPubMed

Yue, X., Wang, P., Xu, J., Zhu, Y., Sun, G., Pang, Q., et al. (2012). MicroRNA-205 functions as a tumor suppressor in human glioblastoma cells by targeting VEGF-A. Oncology Reports, 27(4), 1200–1206. https://doi.org/10.3892/or.2011.1588.CrossRefPubMed

Zhang, F., & Cheong, J. K. (2016). The renewed battle against RAS-mutant cancers. Cellular and Molecular Life Sciences, 73(9), 1845–1858. https://doi.org/10.1007/s00018-016-2155-8.CrossRefPubMed

Zhang, J., Huang, K., O’Neill, K. L., Pang, X., & Luo, X. (2016a). Bax/Bak activation in the absence of Bid, Bim, Puma, and p53. Cell Death & Disease, 7, e2266. https://doi.org/10.1038/cddis.2016.167.CrossRef

Zhang, J. M., Sun, C. Y., Yu, S. Z., Wang, Q., An, T. L., Li, Y. Y., et al. (2011). Relationship between miR-218 and CDK6 expression and their biological impact on glioma cell proliferation and apoptosis. Zhonghua Bing Li Xue Za Zhi, 40(7), 454–459.PubMed

Zhang, K. L., Han, L., Chen, L. Y., Shi, Z. D., Yang, M., Ren, Y., et al. (2014). Blockage of a miR-21/EGFR regulatory feedback loop augments anti-EGFR therapy in glioblastomas. Cancer Letters, 342(1), 139–149. https://doi.org/10.1016/j.canlet.2013.08.043.CrossRefPubMed

Zhang, S., Zhao, B. S., Zhou, A., Lin, K., Zheng, S., Lu, Z., et al. (2017a). m(6)A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program. Cancer Cell, 31(4), 591–606. https://doi.org/10.1016/j.ccell.2017.02.013.CrossRefPubMedPubMedCentral

Zhang, W., Zhang, J., Hoadley, K., Kushwaha, D., Ramakrishnan, V., Li, S., et al. (2012). miR-181d: A predictive glioblastoma biomarker that downregulates MGMT expression. Neuro-Oncology, 14(6), 712–719. https://doi.org/10.1093/neuonc/nos089.CrossRefPubMedPubMedCentral

Zhang, W., Zheng, J., Meng, J., Neng, L., Chen, X., & Qin, Z. (2017b). Macrophage migration inhibitory factor mediates viability and apoptosis of PVM/Ms through PI3K/Akt pathway. Neuroscience, 360, 220–229. https://doi.org/10.1016/j.neuroscience.2017.06.063.CrossRefPubMed

Zhang, X., Zhang, J., Zhang, L., van Dam, H., & ten Dijke, P. (2013). UBE2O negatively regulates TRAF6-mediated NF-kappaB activation by inhibiting TRAF6 polyubiquitination. Cell Research, 23(3), 366–377. https://doi.org/10.1038/cr.2013.21.CrossRefPubMedPubMedCentral

Zhang, X. H., Qian, Y., Li, Z., Zhang, N. N., & Xie, Y. J. (2016b). Let-7 g-5p inhibits epithelial-mesenchymal transition consistent with reduction of glioma stem cell phenotypes by targeting VSIG4 in glioblastoma. Oncology Reports, 36(5), 2967–2975. https://doi.org/10.3892/or.2016.5098.CrossRefPubMed

Zhang, Z., Zhou, Q., Miao, Y., Tian, H., Li, Y., Feng, X., et al. (2015). MiR-429 induces apoptosis of glioblastoma cell through Bcl-2. Tumor Biology. https://doi.org/10.1007/s13277-015-4291-4.CrossRefPubMed

Zhao, H., Shen, J., Hodges, T. R., Song, R., Fuller, G. N., & Heimberger, A. B. (2017). Serum microRNA profiling in patients with glioblastoma: A survival analysis. Molecular Cancer, 16(1), 59. https://doi.org/10.1186/s12943-017-0628-5.CrossRefPubMedPubMedCentral

Zhao, S., Liu, H., Liu, Y., Wu, J., Wang, C., Hou, X., et al. (2013). miR-143 inhibits glycolysis and depletes stemness of glioblastoma stem-like cells. Cancer Letters, 333(2), 253–260. https://doi.org/10.1016/j.canlet.2013.01.039.CrossRefPubMed

Zheng, X., Chopp, M., Lu, Y., Buller, B., & Jiang, F. (2013). MiR-15b and miR-152 reduce glioma cell invasion and angiogenesis via NRP-2 and MMP-3. Cancer Letters, 329(2), 146–154. https://doi.org/10.1016/j.canlet.2012.10.026.CrossRefPubMed

Zhong, Y., Ye, Q., Chen, C., Wang, M., & Wang, H. (2018). Ezh2 promotes clock function and hematopoiesis independent of histone methyltransferase activity in zebrafish. Nucleic Acids Research. https://doi.org/10.1093/nar/gky101.CrossRefPubMedPubMedCentral

Zhou, X., Ren, Y., Moore, L., Mei, M., You, Y., Xu, P., et al. (2010). Downregulation of miR-21 inhibits EGFR pathway and suppresses the growth of human glioblastoma cells independent of PTEN status. Laboratory Investigation, 90(2), 144–155. https://doi.org/10.1038/labinvest.2009.126.CrossRefPubMed

Zhu, J., & Paul, W. E. (2010). Heterogeneity and plasticity of T helper cells. Cell Research, 20(1), 4–12. https://doi.org/10.1038/cr.2009.138.CrossRefPubMed

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Aberrant miRNAs Regulate the Biological Hallmarks of Glioblastoma

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2018

Plasma β-Amyloids and Tau Proteins in Patients with Vascular Cognitive Impairment

Central Orexin A Affects Reproductive Axis by Modulation of Hypothalamic Kisspeptin/Neurokinin B/Dynorphin Secreting Neurons in the Male Wistar Rats

Neuroprotective Effect of Hydrogen Sulfide in Hyperhomocysteinemia Is Mediated Through Antioxidant Action Involving Nrf2

CSF Aβ1–42, but not p-Tau181, Predicted Progression from Amnestic MCI to Alzheimer’s Disease Dementia

DRD3 Gene and ADHD: A Pharmaco-Behavioural Genetic Study

Metabolism of Docosahexaenoic Acid (DHA) Induces Pyroptosis in BV-2 Microglial Cells